Non-Small Cell Lung Cancer Coverage from Every Angle

Julia K. Rotow, MD, on Concurrent Osimertinib Plus Gefitinib in First-Line Treatment of NSCLC

Posted: Wednesday, June 24, 2020

Julia K. Rotow, MD, of Dana-Farber Cancer Institute, discusses findings on the tolerability of combination therapy with osimertinib and gefitinib for first-line treatment of EGFR-mutated non–small cell lung cancer. She describes this dual TKI regimen, and whether this approach might be explored in other settings.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.